Amgen Inc vs. Novavax Inc
Amgen Inc (AMGN) comes out ahead, leading on 5 of 9 compared factors.
Size & Scale
| AMGN | NVAX | |
|---|---|---|
| Market Cap | $236.25 billion | $1.49 billion |
| Revenue (TTM) | $38.09 billion | $413.80 million |
| Net Income (TTM) | $8.74 billion | $-247,730,000 |
AMGN leads on 3 of 3 size & scale factors.
Valuation
| AMGN | NVAX | |
|---|---|---|
| P/E Ratio | 27.14 | — |
| Price / Book | 20.21 | -7.83 |
| Price / Sales | 6.20 | 3.61 |
NVAX leads on 2 of 2 valuation factors.
Profitability
| AMGN | NVAX | |
|---|---|---|
| Net Margin | 22.95% | -59.87% |
| Return on Equity | 74.80% | 129.90% |
AMGN and NVAX split the profitability factors evenly.
Dividend
| AMGN | NVAX | |
|---|---|---|
| Dividend Yield | 2.31% | 14.09% |
| Payout Ratio | 62.61 | — |
NVAX leads on 1 of 1 dividend factors.
Risk & Sentiment
| AMGN | NVAX | |
|---|---|---|
| Short Interest | 1.66% | 25.98% |
AMGN leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, NVAX overview, NVAX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.